REAL-WORLD EFFECTIVENESS OF ECULIZUMAB, SWITCH TO RAVULIZUMAB AND RAVULIZUMAB AS FIRST THERAPY IN SWISS PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

被引：0
|
作者：
Rovo, A. [1 ,2 ]
Simeon, L. [3 ]
Gavillet, M. [4 ,5 ,6 ]
Samii, K. [7 ]
Cantoni, N. [8 ]
Drexler, B. [9 ]
Stussi, G. [10 ]
Bissig, M. [11 ]
机构：
[1] Univ Hosp Bern, Dept Hematol, Inselspital, Bern, Switzerland
[2] Univ Hosp Bern, Cent Hematol Lab, Inselspital, Bern, Switzerland
[3] Cantonal Hosp Lucerne, Dept Hematol, Luzern, Switzerland
[4] Lausanne Univ Hosp CHUV, Dept Oncol, Serv & Cent Lab Hematol, Lausanne, Switzerland
[5] Lausanne Univ Hosp CHUV, Dept Lab Med & Pathol, Lausanne, Switzerland
[6] Ctr Lausannes Epalinges, Interreg Blood Tranfus SRC, Epalinges, Switzerland
[7] Geneva Univ Hosp, Div Hematol, Dept Oncol, Geneva, Switzerland
[8] Cantonal Hosp Aarau, Div Oncol Hematol & Tranfus Med, Aarau, Switzerland
[9] Univ Hosp Basel, Dept Hematol, Basel, Switzerland
[10] Oncol Inst Southern Switzerland, Clin Hematol, Bellinzona, Switzerland
[11] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2023年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
225
引用
收藏
页码：30S / 31S
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD DOSING PATTERNS OF ECULIZUMAB-NAIVE AND ECULIZUMAB-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING RAVULIZUMAB IN THE US
    Cheng, W. Y.
    Fishman, J.
    Yenikomshian, M.
    Mahendran, M.
    Kunzweiler, C.
    Vu, J. D.
    Duh, M. S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S493 - S493
  • [2] Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
    Cheng, Wendy Y.
    Fishman, Jesse
    Sarda, Sujata P.
    Krishnan, Sangeeta
    Kunzweiler, Colin
    Vu, Jensen Duy
    Yenikomshian, Mihran
    Duh, Mei Sheng
    [J]. BLOOD, 2021, 138
  • [3] Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
    S. W. Quist
    A. J. Postma
    K. J. Myrén
    L. A. de Jong
    M. J. Postma
    [J]. The European Journal of Health Economics, 2023, 24 : 1455 - 1472
  • [4] Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
    Quist, S. W.
    Postma, A. J.
    Myren, K. J.
    de Jong, L. A.
    Postma, M. J.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (09): : 1455 - 1472
  • [5] COST-EFFECTIVENESS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE NETHERLANDS
    Quist, S.
    Postma, A. J.
    Myren, K. J.
    de Jong, L.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S99 - S99
  • [6] PATIENT AND PHYSICIAN SATISFACTION OF TREATMENT WITH ECULIZUMAB OR RAVULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM A REAL-WORLD DISEASE-SPECIFIC PROGRAMME
    Fureder, W.
    Mellor, J.
    Earl, L.
    Wang, A.
    Patel, Y.
    Myren, K. J.
    Nagalla, S.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S347 - S347
  • [7] Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
    Thomas O’Connell
    Marric Buessing
    Scott Johnson
    Lufei Tu
    Simu K. Thomas
    Ioannis Tomazos
    [J]. PharmacoEconomics, 2020, 38 : 981 - 994
  • [8] COST-UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    OConnell, T.
    Buessing, M. G.
    Johnson, S. J.
    Tu, L.
    Tomazos, I
    Thomas, S. K.
    [J]. VALUE IN HEALTH, 2019, 22 : S341 - S341
  • [9] Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
    O'Connell, Thomas
    Buessing, Marric
    Johnson, Scott
    Tu, Lufei
    Thomas, Simu K.
    Tomazos, Ioannis
    [J]. PHARMACOECONOMICS, 2020, 38 (09) : 981 - 994
  • [10] Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab
    Tomazos, Ioannis
    Sierra, J. Rafael
    Johnston, Karissa M.
    Cheung, Antoinette
    Brodsky, Robert A.
    Weitz, Ilene C.
    [J]. HEMATOLOGY, 2020, 25 (01) : 327 - 334
12345